JP5890407B2 - 呼吸器合胞体ウイルス抗原組成物および方法 - Google Patents

呼吸器合胞体ウイルス抗原組成物および方法 Download PDF

Info

Publication number
JP5890407B2
JP5890407B2 JP2013518819A JP2013518819A JP5890407B2 JP 5890407 B2 JP5890407 B2 JP 5890407B2 JP 2013518819 A JP2013518819 A JP 2013518819A JP 2013518819 A JP2013518819 A JP 2013518819A JP 5890407 B2 JP5890407 B2 JP 5890407B2
Authority
JP
Japan
Prior art keywords
rsv
polypeptide
epitope
peptide
polyelectrolyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013518819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535428A5 (OSRAM
JP2013535428A (ja
Inventor
トーマス ジェイ． パウエル、
トーマス ジェイ． パウエル、
ジェイムズ ゴルハム ボイド、
ジェイムズ ゴルハム ボイド、
Original Assignee
アーティフィシャル セル テクノロジーズ インコーポレイテッド
アーティフィシャル セル テクノロジーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーティフィシャル セル テクノロジーズ インコーポレイテッド, アーティフィシャル セル テクノロジーズ インコーポレイテッド filed Critical アーティフィシャル セル テクノロジーズ インコーポレイテッド
Publication of JP2013535428A publication Critical patent/JP2013535428A/ja
Publication of JP2013535428A5 publication Critical patent/JP2013535428A5/ja
Application granted granted Critical
Publication of JP5890407B2 publication Critical patent/JP5890407B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2013518819A 2010-07-07 2011-07-07 呼吸器合胞体ウイルス抗原組成物および方法 Active JP5890407B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36202910P 2010-07-07 2010-07-07
US61/362,029 2010-07-07
US201161485669P 2011-05-13 2011-05-13
US61/485,669 2011-05-13
PCT/US2011/043136 WO2012006395A1 (en) 2010-07-07 2011-07-07 Respiratory syncytial virus antigenic compositions and methods

Publications (3)

Publication Number Publication Date
JP2013535428A JP2013535428A (ja) 2013-09-12
JP2013535428A5 JP2013535428A5 (OSRAM) 2014-08-07
JP5890407B2 true JP5890407B2 (ja) 2016-03-22

Family

ID=45438747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518819A Active JP5890407B2 (ja) 2010-07-07 2011-07-07 呼吸器合胞体ウイルス抗原組成物および方法

Country Status (13)

Country Link
US (1) US9487593B2 (OSRAM)
EP (1) EP2590675B1 (OSRAM)
JP (1) JP5890407B2 (OSRAM)
CN (2) CN103037898B (OSRAM)
AU (1) AU2011276251B2 (OSRAM)
BR (1) BR112013000345B1 (OSRAM)
CA (1) CA2799934C (OSRAM)
DK (1) DK2590675T3 (OSRAM)
ES (1) ES2688993T3 (OSRAM)
IL (1) IL222723B (OSRAM)
MX (1) MX340796B (OSRAM)
RU (1) RU2609661C2 (OSRAM)
WO (1) WO2012006395A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9433671B2 (en) 2012-03-30 2016-09-06 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
US8883717B2 (en) 2012-03-30 2014-11-11 Artificial Cell Technologies, Inc. Antigenic compositions and methods
EA201891945A3 (ru) * 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
CN105555301B (zh) 2013-08-13 2021-04-16 西北大学 肽缀合颗粒
CN106457302B (zh) 2014-05-27 2020-04-17 人工细胞科技公司 通过tff进行多层涂覆芯的自动化逐层构造
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
US9968665B2 (en) 2015-09-16 2018-05-15 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
US20170230649A1 (en) * 2016-02-05 2017-08-10 Qualcomm Incorporated Calibration of hybrid auto focus (af) imaging systems
SG11201908999QA (en) 2017-04-04 2019-10-30 Univ Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
US11773143B2 (en) 2017-10-13 2023-10-03 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus G protein central conserved region
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
EP3833677A4 (en) 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED RSV PASSIVE AND ACTIVE VACCINES
US20230414526A1 (en) * 2022-03-29 2023-12-28 Artificial Cell Technologies, Inc. Respiratory syncytial virus antigenic compositions and methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677090B2 (en) * 1993-08-06 1997-04-10 Connaught Laboratories Limited Inactivated respiratory syncytial viral vaccines
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
ATE178906T1 (de) 1994-08-25 1999-04-15 Stichting Inst Dierhouderij Antigene peptide abgeleitet vom g-protein des rsv (respiratorisches synzytialvirus) für die typen- und subtypen spezifische diagnose einer rsv- infektionen
FR2726471B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
ES2316487T5 (es) 2000-10-18 2019-05-13 The Government Of The Us Secretary Department Of Health And Human Services Composiciones y métodos para modular la inmunidad e infección de RSV
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
AUPR520201A0 (en) 2001-05-23 2001-06-14 Commonwealth Scientific And Industrial Research Organisation Antiviral compounds
JP3997930B2 (ja) 2003-02-27 2007-10-24 富士ゼロックス株式会社 カーボンナノチューブの製造装置および製造方法
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
US7615530B2 (en) 2003-08-29 2009-11-10 Artificial Cell Technologies, Inc. Immunogenic compositions and methods of use
US7348399B2 (en) * 2003-08-29 2008-03-25 Louisiana Tech University Foundation, Inc. Nanofabricated polypeptide multilayer films, coatings, and microcapsules
EP1768993A4 (en) 2004-06-16 2008-07-23 Univ Johns Hopkins CYSTIC REGION OF HUMAN RESPIRATORY SYNZYTIAL VIRUS AND METHOD OF USE THEREOF
US20080131450A1 (en) 2004-07-23 2008-06-05 Pierre Fabre Medicament Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions
US20080171070A1 (en) * 2005-01-31 2008-07-17 Pierre Schaaf Polyelectrolyte Multilayer Film, Preparation And Uses Thereof
US20090220537A1 (en) * 2005-04-12 2009-09-03 The University Of Queensland Vaccine delivery system
EP2308900B1 (en) 2005-10-25 2014-02-12 Artificial Cell Technologies, Inc. Immunogenic compositions and methods of use
EP1972348A1 (en) 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
CA2684578A1 (en) 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
US7723294B2 (en) * 2007-04-02 2010-05-25 Artificial Cell Technologies, Inc. Polypeptide films and methods
WO2009079066A2 (en) * 2007-09-26 2009-06-25 Aparna Biosciences Therapeutic and vaccine polyelectrolyte nanoparticle compositions
EP2058002A1 (en) * 2007-10-31 2009-05-13 Bestewil Holding B.V. Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine
US20110177117A1 (en) 2008-07-18 2011-07-21 Normand Blais Chimeric respiratory syncytial virus polypeptide antigens
WO2010075491A2 (en) 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
CA2770304C (en) 2009-08-04 2019-11-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Anti-rsv immunogens and methods of immunization
US8883717B2 (en) * 2012-03-30 2014-11-11 Artificial Cell Technologies, Inc. Antigenic compositions and methods

Also Published As

Publication number Publication date
CN106008716B (zh) 2019-08-13
IL222723A0 (en) 2012-12-31
MX2012015030A (es) 2013-06-13
US20120009254A1 (en) 2012-01-12
BR112013000345A2 (pt) 2016-05-31
AU2011276251A2 (en) 2013-01-24
CA2799934A1 (en) 2012-01-12
WO2012006395A1 (en) 2012-01-12
CN106008716A (zh) 2016-10-12
MX340796B (es) 2016-07-27
CN103037898A (zh) 2013-04-10
CA2799934C (en) 2020-01-28
RU2609661C2 (ru) 2017-02-02
CN103037898B (zh) 2016-06-29
DK2590675T3 (en) 2018-10-29
AU2011276251A1 (en) 2012-11-08
EP2590675B1 (en) 2018-08-29
EP2590675A1 (en) 2013-05-15
ES2688993T3 (es) 2018-11-07
AU2011276251B2 (en) 2015-02-05
RU2013101972A (ru) 2014-08-20
JP2013535428A (ja) 2013-09-12
US9487593B2 (en) 2016-11-08
IL222723B (en) 2020-03-31
BR112013000345B1 (pt) 2021-11-23

Similar Documents

Publication Publication Date Title
US9487593B2 (en) Respiratory syncytial virus antigenic compositions and methods
US9925252B2 (en) Antigenic compositions and methods
JP6335876B2 (ja) マラリアに対するマイクロ粒子ワクチン
JP6934862B2 (ja) 抗マラリア組成物および方法
US20230414526A1 (en) Respiratory syncytial virus antigenic compositions and methods
CA3112575A1 (en) Anti-malaria compositions and methods
HK1206972B (en) Microparticle/nanoparticle vaccine against malaria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160218

R150 Certificate of patent or registration of utility model

Ref document number: 5890407

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250